SGLT2 inhibitor Archives - Medical Conferences

Sotagliflozin SCORED MACE benefit

Presented By

Prof. Deepak Bhatt, Brigham and Women's Hospital, USA

Trial

Phase 3, SCORED

Conference

ACC 2022

15 June, 2022 14:57

Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes

Presented By

Dr Ameenathul Fawzy, Liverpool Heart and Chest Hospital, UK

Conference

EHRA 2022

1 June, 2022 11:03

Empagliflozin efficacious in HF patients with preserved ejection fractions ≥50%

Presented By

Dr Stefan Anker, Charité University Berlin, Germany

Trial

EMPEROR-Preserved

Conference

AHA 2021

14 January, 2022 15:15

EMPULSE: Empagliflozin improves outcomes of acute heart failure

Presented By

Prof. Adriaan Voors, University of Groningen, the Netherlands

Trial

Phase 3, EMPULSE

Conference

AHA 2021

14 January, 2022 15:03

Therapeutic approaches in heart failure with diabetes

Presented By

Prof. Lynne Stevenson, Vanderbilt University Medical Center, USA

Conference

AHA 2021

14 January, 2022 14:48

Empagliflozin linked to lower cardiovascular risk and renal events in real-world study

Presented By

Prof. Leo Niskanen, University of Eastern Finland, Finland

Conference

HFA 2021

19 August, 2021 09:43

Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status

Presented By

Prof. Faiez Zannad, University of Lorraine, France

Trial

EMPEROR-Reduced; DAPA=HF; DAPA-CKD; EMPA-Kideney

Conference

HFA 2021

19 August, 2021 09:39

Biomarker panel predicts SGLT2 inhibitor response

Presented By

Dr Muthiah Vaduganathan, Brigham and Women´s Hospital, MA, USA

Trial

CANVAS

Conference

HFA 2021

19 August, 2021 09:33

Dapagliflozin fails to show a significant protective effect in COVID-19

Presented By

Prof. Mikhail Kosiborod, Saint Luke’s Mid America Heart Institute, USA

Trial

DARE-19

Conference

ACC 2021

9 July, 2021 23:46

Dapagliflozin reduces renal risk independent of CV disease status

Presented By

Prof. John McMurray, University of Glasgow, Scotland

Trial

DAPA-CKD

Conference

AHA 2020

18 February, 2021 10:18

Ertugliflozin offers some kidney protection

Presented By

Prof. David Cherney, University of Toronto, Canada

Trial

VERTIS CV

Conference

EASD 2020

14 December, 2020 12:44

Poor prognosis for T2D patients on loop diuretics in addition to SGLT2 inhibitor

Presented By

Prof. Pierpaolo Pellicori, University of Glasgow, United Kingdom

Trial

EMPA-REG OUTCOME

Conference

EASD 2020

14 December, 2020 12:39